11,412 Shares in OmniAb, Inc. (NASDAQ:OABI) Purchased by Choreo LLC

Choreo LLC acquired a new stake in OmniAb, Inc. (NASDAQ:OABI) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 11,412 shares of the company’s stock, valued at approximately $41,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Murchinson Ltd. bought a new stake in OmniAb during the third quarter worth $4,230,000. Rice Hall James & Associates LLC boosted its stake in shares of OmniAb by 6.4% during the third quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company’s stock valued at $11,515,000 after purchasing an additional 163,038 shares in the last quarter. Barclays PLC raised its holdings in OmniAb by 321.5% in the 3rd quarter. Barclays PLC now owns 143,215 shares of the company’s stock valued at $606,000 after buying an additional 109,236 shares during the last quarter. BBR Partners LLC increased its position in OmniAb by 250.0% in the 3rd quarter. BBR Partners LLC now owns 70,000 shares of the company’s stock valued at $296,000 after acquiring an additional 50,000 shares during the period. Finally, The Manufacturers Life Insurance Company acquired a new stake in OmniAb in the second quarter valued at $147,000. Institutional investors own 72.08% of the company’s stock.

OmniAb Stock Up 4.7 %

OABI stock opened at $3.81 on Monday. The business has a 50 day moving average of $3.51 and a 200-day moving average of $3.92. The firm has a market cap of $538.05 million, a PE ratio of -6.15 and a beta of -0.12. OmniAb, Inc. has a 12-month low of $3.10 and a 12-month high of $6.55.

Insider Activity at OmniAb

In other news, insider Charles S. Berkman sold 25,489 shares of OmniAb stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total value of $82,584.36. Following the completion of the transaction, the insider now directly owns 343,190 shares in the company, valued at approximately $1,111,935.60. The trade was a 6.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Matthew W. Foehr sold 41,811 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total transaction of $135,467.64. Following the completion of the sale, the chief executive officer now directly owns 3,749,639 shares in the company, valued at approximately $12,148,830.36. The trade was a 1.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 82,826 shares of company stock worth $268,356. Insiders own 8.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on OABI. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of OmniAb in a research note on Thursday, November 14th. Benchmark restated a “buy” rating and set a $8.00 price objective on shares of OmniAb in a report on Thursday, November 14th.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.